Description: Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and cervical cancer; and ITIL-306 (FOLR1) with indications, including gynecological, non-small cell lung cancer, and others. The company was incorporated in 2018 and is based in Dallas, Texas.
Home Page: instilbio.com
TIL Technical Analysis
3963 Maple Avenue
Dallas,
TX
75219
United States
Phone:
972 499 3350
Officers
| Name | Title |
|---|---|
| Mr. Bronson Crouch | Chairman & CEO |
| Dr. Sandeep Laumas M.D. | CFO & Chief Bus. Officer |
| Mr. Timothy L. Moore | Chief Operating Officer |
| Dr. Mark E. Dudley Ph.D. | Chief Scientific Officer |
| Ms. Sumita Ray J.D. | Chief Legal, Compliance, & Admin. Officer |
| Dr. Robert Hawkins MBBS, Ph.D. | Head of R&D |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3027 |
| Price-to-Sales TTM: | 55329.793 |
| IPO Date: | 2021-03-19 |
| Fiscal Year End: | December |
| Full Time Employees: | 412 |